Loading
Cell therapies are tested for purity and count, but not for whether they can actually kill that patient's tumour. Testing them against the patient's own mini-tumour would show this.
Release criteria for CAR-T and TIL products measure viability, transduction and sterility, not tumour-specific cytotoxicity. Co-culturing an aliquot of the product with the patient's own organoid or tumour slice gives a functional potency assay with a killing readout. This could flag likely non-responders before lymphodepletion, and provide a comparator when choosing between products or targets.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.
Shares Estimation of clinical trial success rates and related parameters, TIL therapy, Lab models that fail to predict what happens in patients, Patient-derived organoids.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients, Patient-derived organoids.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients, Patient-derived organoids.
Shares TIL therapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Estimation of clinical trial success rates and related parameters, Lab models that fail to predict what happens in patients, Patient-derived organoids.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/